קליידקו 150 מ"ג טבליות מצופות - Kalydeco 150 mg film coated tablets
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | R07AX Other respiratory system products | ||||||||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||||||||||||||||||||
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||||||||
| ×ת×××× |
Kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data. Limitations of use : Kalydeco is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene.
| ||||||||||||||||||||||||
| |||||||||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||||||||
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ק×××××§× 150 ×"× ×××××ת ×צ×פ×ת ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | VERTEX PHARMACEUTICALS (EUROPE) LIMITED, UK |
| ×©× ××¢× ×ר×ש×× | VERTEX PHARMACEUTICALS (U.K) LIMITED, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 8/2014. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 16/05/2024 |
השינוי האחרון נעשה בֹ־16 במאי 2024 ב־16:21